Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: It is uncertain whether pharmacological reductions in very‐low‐density lipoproteins (VLDLs), and their component triglyceride and cholesterol could reduce residual risk of atherosclerotic cardiovascular disease (ASCVD) events among individuals in whom low‐density lipoprotein cholesterol (LDL‐C) has been adequately lowered. We examined whether individuals with greater on‐statin reductions in VLDL‐related measures—beyond reductions in LDL‐C—were at further reduced risk of ASCVD. Methods and Results: In 9423 participants in the JUPITER (Justification for the Use of Statins in Prevention) trial (NCT00239681), at baseline and on statin we measured standard lipids, 400‐MHz proton nuclear magnetic resonance spectroscopy‐measured VLDL particle subclasses (small, medium, and large VLDL lipoprotein particle concentration), and total VLDL cholesterol mass. Compared with individuals allocated to placebo, we examined risk of incident ASCVD (N=211) among statin‐allocated participants who achieved minimal (<median) or greater (≥median) marker reductions using adjusted Cox models. On‐statin changes in VLDL‐related markers were only modestly correlated (Spearman r ≤0.29) with change in LDL‐C. On‐statin median LDL‐C was 54 mg/dL and triglyceride was 101 mg/dL. Dose‐response reductions in ASCVD risk were observed for greater reductions in LDL‐C, VLDL cholesterol mass, and small VLDL lipoprotein particle concentration; the latter 2 remained significant after incremental adjustment for change in LDL‐C ( P ≤0.006). Conversely, there was no further risk reduction with greater reductions in triglycerides or large/medium VLDL lipoprotein particle concentration. Conclusions: Pharmacological reduction in small, cholesterol‐enriched, triglyceride‐depleted VLDL was associated with reduction in ASCVD risk. Chemically measured triglycerides may not sufficiently capture risk related to VLDL pathways. These findings also support broader profiling of lipid and lipoprotein changes in response to statins as prognostic markers of individual benefit, supporting more precision‐medicine, individualized approaches to cardiovascular risk reduction. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00239681.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citationTrends in Lipids and Lipoproteins in US Adults, 1988-2010
Carroll, M. D., Kit, B. K., Lacher, D. A., Shero, S. T., & Mussolino, M. E. (2012) · JAMA · doi:10.1001/jama.2012.13260 · Cited by 282
Shin, H. K., Kim, Y. K., Kim, K. Y., Lee, J. H., & Hong, K. W. (2004) · Circulation · doi:10.1161/01.cir.0000117403.64398.53 · Cited by 268
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260 · cited 2×
“The implementation of broad pharmacological- and lifestyle-based preventive strategies targeting LDL-C has resulted in appreciable reductions in LDL-C on the population level.1–3 At the same time, there is histopathological evidence that the composition and morphology of human atherosclerotic plaque has changed in rec…”
Combination lipid therapy in type 2 diabetes
(2010) · New England Journal of Medicine · doi:10.1056/nejmc1006407 · Cited by 245
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Lawler, P. R., Akinkuolie, A. O., Chu, A. Y., Shah, S. H., Kraus, W. E., Craig, D., Padmanabhan, L., Glynn, R. J., Ridker, P. M., Chasman, D. I., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005549 · Cited by 145
Self-citation
Cited by
Dyslipidemia and cardiovascular disease risk among the MASHAD study population
Hedayatnia, M., Asadi, Z., Zare-Feyzabadi, R., Yaghooti-Khorasani, M., Ghazizadeh, H., Ghaffarian-Zirak, R., Nosrati-Tirkani, A., Mohammadi-Bajgiran, M., Rohban, M., Sadabadi, F., et al. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01204-y · Cited by 367
Langlois, M. R., Chapman, M. J., Cobbaert, C., Mora, S., Remaley, A. T., Ros, E., Watts, G. F., Borén, J., Baum, H., Bruckert, E., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.287037 · Cited by 260
Self-citationLawler, P. R., Kotrri, G., Koh, M., Goodman, S. G., Farkouh, M. E., Lee, D. S., Austin, P. C., Udell, J. A., & Ko, D. T. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz767 · Cited by 113
Self-citationMetabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034942 · Cited by 109
“We also observed a difference in lowering of VLDLcholesterol levels; the cholesterol concentrations of VLDL particles are strongly associated with risk of myocardial infarction (44) and some studies have suggested that VLDL-cholesterol could underpin the link between triglycerides and cardiovascular risk (38,41).”
BackgroundResultRosenson, R. S., Daviglus, M. L., Handelsman, Y., Pozzilli, P., Bays, H., Monsalvo, M. L., Elliott-Davey, M., Somaratne, R., & Reaven, P. (2019) · Diabetologia · doi:10.1007/s00125-019-4856-7 · Cited by 73
Metadata
- Authors
- Lawler, P. R., Akinkuolie, A. O., Harada, P., Glynn, R. J., Chasman, D. I., Ridker, P. M., & Mora, S.
- Venue
- Journal of the American Heart Association
- Published
- 2017-12-02
- Volume
- 6
- Issue
- 12
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2772281339
- Cited by
- 69
- References
- 12
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins. https://app.cochat.ai/papers/10.1161/jaha.117.007402
- The paper
- Lawler, P. R., Akinkuolie, A. O., Harada, P., Glynn, R. J., Chasman, D. I., Ridker, P. M., & Mora, S. (2017). Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins. Journal of the American Heart Association. https://doi.org/10.1161/jaha.117.007402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.